Aro Biotherapeutics

Aro Biotherapeutics

  • Founded: 2017
  • Location: Philadelphia, PA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Pompe Disease (ODD)
  • Drug types: GEN, PED, MUS, IMM
  • Lead product: ABX1100
  • Product link:
  • Funding: $24M B Jan 2023; $88M A Jan 2021; $13M Dec 2018
  • Investors: Cowen Healthcare

job board

Short description:

Protein Scaffolds, Antisense Oligonucleotide

Drug notes:

Undisclosed RD genetic muscle disease; undisclosed RD immune disease

Long description:

Aro Biotherapeutics is using their proprietary protein technology called Centyrins to address previously intractable diseases. Centyrins are small, engineered proteins derived from the human protein Tenascin C, a protein which is found in the extracellular matrix of tissues. By modifying the amino acid sequence of Centyrins, Aro has created a library of trillions of Centyrins variants that bind with high affinity and specificity against different antigens of interest. Aro is using this starting library to optimize Centyrins for desired tissue specificity. Once Centyrins have been optimized, they can be conjugated with drug payloads such as oligonucleotides. With this approach, Aro is pioneering a new class of tissue-targeted genetic medicines to treat disease.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy